Clinical trial • Not applicable • Musculoskeletal|Neurology
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Postmastectomy pain syndrome
Not applicable trial of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Postmastectomy pain syndrome.
Overview
- Trial Therapeutic Area
- Musculoskeletal|Neurology
- Trial Disease
- Postmastectomy pain syndrome
- Trial Stage
- Not applicable
- Drug Modality
- Peptide/protein/enzyme|Small molecule
Key dates
- Initial CTIS Submission Date
- 26-06-2024
- First CTIS Authorization Date
- 04-09-2024
Trial design
Randomised, xeomin (incobotulinumtoxina / clostridium botulinum neurotoxin type a) 100 u, intramuscular injection; qutenza (capsaicin) 179 mg cutaneous patch (transdermal).-controlled Not applicable trial across 1 site in Spain.
- Randomised
- Yes
- Comparator
- XEOMIN (incobotulinumtoxinA / Clostridium botulinum neurotoxin type A) 100 U, intramuscular injection; Qutenza (capsaicin) 179 mg cutaneous patch (transdermal).
- Target Sample Size
- 30
Eligibility
Recruits 30 No vulnerable populations selected; only adult women (>18 years). Signed informed consent is required from participants; subject information and informed consent form available..
- Vulnerable Population
- No vulnerable populations selected; only adult women (>18 years). Signed informed consent is required from participants; subject information and informed consent form available.
Inclusion criteria
- {"criterion_text":"- Women over 18 years of age operated on for unilateral breast neoplasia\n- Patients with painful symptoms defining postmastectomy syndrome.\n- Patients with moderate-severe pain.\n- Signed informed consent form."}
Exclusion criteria
- {"criterion_text":"- Age less than 18 years\n- Presence of cognitive-behavioral deficits.\n- Patients with bilateral tumor involvement, cases of tumor recurrence, patients referred for non-oncologic breast surgery.\n- Non-acceptance to participate in the study.\n- Breast tumors in men."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Pain assessment: Recording of pain intensity using a visual analogue scale (VAS)","definition_or_measurement_approach":"Recording of pain intensity using a visual analogue scale (VAS)."}
- {"endpoint_text":"- Characterization of the predominant pain perception: burning, stabbing pain, sensation of pressure or numbness.","definition_or_measurement_approach":"Characterisation of the predominant pain perception as burning, stabbing pain, sensation of pressure or numbness (as recorded in study assessments)."}
Secondary endpoints
- {"endpoint_text":"- Recording of side effects","definition_or_measurement_approach":"Recording and reporting of adverse events/side effects."}
- {"endpoint_text":"- Recording of the degree of patient satisfaction","definition_or_measurement_approach":"Recording of patient satisfaction (degree) as per study assessments."}
- {"endpoint_text":"- Recording of concomitant analgesic medications","definition_or_measurement_approach":"Recording of concomitant analgesic medication use."}
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 15
- Consent Approach
- Signed informed consent form required from participants (adult women). Subject information and informed consent form available (document L1). Study materials and translations include Spanish.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Spain
- Earliest CTIS Part Ii Submission Date
- 02-08-2024
- Latest Decision Or Authorization Date
- 04-09-2024
- Processing Time Days
- 33
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Hospital Universitario Dr Peset Aleixandre
- Department Name
- physical medicine and rehabilitation
- Principal Investigator Name
- Maria Rosario Beseler Soto
- Principal Investigator Email
- beseler_ros@gva.es
- Contact Person Name
- Maria Rosario Beseler Soto
- Contact Person Email
- beseler_ros@gva.es
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
- Organisation Type
- Patient organisation/association
- Country Of Registered Address
- Spain
Third parties
- {"country":"","full_name":"Merz Therapeutics","duties_or_roles":"Monetary support","organisation_type":""}
- {"country":"","full_name":"Hospital Universitario Doctor Peset","duties_or_roles":"Monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- XEOMIN 100 unidades polvo para solución inyectable
- Active Substance
- CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- Intramuscular
- Route
- Intramuscular
- Authorisation Status
- Authorised (marketing authorisation number 69292)
- Maximum Dose
- 100 U
- Investigational Product Name
- Qutenza 179 mg cutaneous patch
- Active Substance
- CAPSAICIN
- Modality
- Small molecule
- Routes Of Administration
- Transdermal
- Route
- Transdermal
- Authorisation Status
- Authorised (marketing authorisation EU/1/09/524/001)
- Maximum Dose
- 179 mg
Related trials
Other published trials that may interest you.
- Pregabalin for Spinal cord injury (SCI) | Spasticity (spastic motor behaviour)
- MEXILETINE HYDROCHLORIDE for Non-dystrophic myotonias | Myotonia congenita | Paramyotonia congenita | Sodium channel myotonia
- Botulinum toxin type A for Post-stroke spasticity
- Humanised IgG1 kappa fragment antibody targeting TFR1 conjugated to P125 oligonucleotide for Myotonic dystrophy type 1
- DEXMEDETOMIDINE for Breast cancer